Is type 2 hepatorenal syndrome still a potential indication for treatment with terlipressin and albumin?

Publisher： John Wiley & Sons Inc

E-ISSN： 1527-6473|21|11|1335-1337

ISSN： 1527-6465

Source： LIVER TRANSPLANTATION, Vol.21, Iss.11, 2015-11, pp. : 1335-1337

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial

By  

HEPATOLOGY, Vol. 62, Iss. 2, 2015-08 ,pp. : 567-574

John Wiley & Sons Inc

Access to resources Recommend Favorite

Terlipressin therapy for reversal of type 1 hepatorenal syndrome: A meta‐analysis of randomized controlled trials

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 25, Iss. 5, 2010-05 ,pp. : 880-885

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment of type 2 hepatorenal syndrome in patients awaiting transplantation: Effects on kidney function and transplantation outcomes

By  

LIVER TRANSPLANTATION, Vol. 21, Iss. 11, 2015-11 ,pp. : 1347-1354

John Wiley & Sons Inc

Access to resources Recommend Favorite

Outcomes of patients with cirrhosis and hepatorenal syndrome type 1 treated with liver transplantation

By  

LIVER TRANSPLANTATION, Vol. 21, Iss. 3, 2015-03 ,pp. : 300-307

John Wiley & Sons Inc

Access to resources Recommend Favorite

Acute kidney injury

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 30, Iss. 2, 2015-02 ,pp. : 236-243

John Wiley & Sons Inc

Access to resources Recommend Favorite